Rafael G. Amado
President and Head of Global Research & DevelopmentDr. Rafael G. Amado, M.D., has been a Director of Synnovation Therapeutics since May 2025. He is Head of Global Research & Development of Zai Lab Limited from June 30, 2024 and serves as its President since December 30, 2022 and was its Head of Global Oncology Research and Development from December 30, 2022 to June 30, 2024. He serves as Director at Poseida Therapeutics, Inc. since April 2023. He was Director at Notch Therapeutics Inc. He had been an Executive Vice President of Research and Development at Allogene Therapeutics, Inc. since September 3, 2019 until December 30, 2022. Dr. Amado serves as a Member of Scientific Advisory Board at ReCode Therapeutics, Inc., since November 2022. He served as Chief Medical Officer at Allogene Therapeutics, Inc. since September 3, 2019 until December 2022. Dr. Amado served as the President of Research & Development at Adaptimmune Therapeutics plc from August 1, 2018 to August 12, 2019 and served as its Chief Medical Officer since March 16, 2015 until August 1, 2018. He leads Adaptimmune's clinical strategy and is responsible for clinical trials across the U.S. and Europe under strategic collaboration with GSK, as well as leading the development of pipeline of wholly-owned research programs. He has many years of biotechnology and pharmaceutical industry experience leading clinical and research teams. He served as the Head of Oncology Research & Development of GlaxoSmithKline Inc. (GSK). Dr. Amado served as Head of Research and Development at Allogene Therapeutics, Inc. from September 2019 to December 2022. Prior to joining Amgen, he held academic roles at the University of California, Los Angeles (UCLA) in the Department of Medicine, Division of Hematology/Oncology. He was responsible for integrating oncology R&D activities, from drug target identification to clinical development and registration globally. He joined GSK in 2008 as Vice President of Clinical Development and served in positions of increasing responsibility, including Senior Vice President and Head of Oncology Clinical Development. He oversaw the development and registration globally of over 15 novel indications across six products and led the development of a pipeline of products in novel areas of cancer biology. Prior to joining GSK, he served as an Executive Director of Therapeutic Oncology at Amgen from 2003 to 2008, where he was responsible for development activities of several assets. He trained as a Hematologist/Oncologist at the University of California, Los Angeles, where he remained as faculty for many years until joining Amgen in 2003. He holds an M.D. from the University of Seville School of Medicine and performed his residency in Internal Medicine at Michael Reese Hospital, a formerly University of Chicago Affiliated Hospital and his fellowship in Hematology/Oncology at the University of California, Los Angeles.
Positions
- Company NameZai Lab LimitedStock Code09688PositionPresident and Head of Global Research & DevelopmentRelated SecuritiesColleagues
- YDYing DuFounder, Chairperson & CEO
- YCYajing ChenChief Financial Officer
- FTFrazor Titus EdmondsonChief Legal Officer & Corporate Secretary
- CCChristine ChiouSenior VP & Head of Investor Relations
- PKPeter Karl WirthIndependent Director
- JDJohn David DiekmanLead Independent Director
- SWScott William MorrisonIndependent Director
- WDWilliam David LisIndependent Director
